RECRUITING

Sacral Neuromodulation for Chronic Pelvic Pain

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

Official Title

Sacral Neuromodulation for the Treatment of Chronic Pelvic Pain

Quick Facts

Study Start:2025-06

Study Completion:2028-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06150599

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years to 70 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Female, aged 22-70 4. Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient) 5. Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations) 6. No changes to current regimen of medications for their pelvic pain for \> 4 weeks prior to screening 7. For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation 8. Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)	1. History of any active pelvic cancer 2. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints 3. Concurrent pain management strategies within the past 3 months that may interfere or mask study intervention (e.g. pelvic floor physical therapy, shockwave therapy, trigger point injections, bladder instillations) 4. Any psychiatric or personality disorder at the discretion of the study physician. This does not include depression or generalized anxiety disorders that are stable. 5. Current symptomatic urinary tract infection (UTI) or more than 6 UTIs in past year 6. Severe or uncontrolled diabetes (A1C \> 7, documented in the last 3 months) or diabetes with peripheral nerve involvement 7. Interstitial cystitis diagnosis with Hunner's lesions as this is a severe inflammatory bladder condition that can only be treated with eradication of the lesions or a cystectomy. SNM would be be expected to help for IC with Hunner's lesions 8. Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial 9. Subject with documented history of allergy to titanium, zirconia, polyurethane, epoxy, or silicone 10. Implantation of spinal cord stimulator and/or drug delivery pumps, whether turned on or off 11. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception 12. Current treatment for active malignancy (skin cancers excluded) 13. Patients with spinal pathology that could confound study results. This may include participants with cauda equina syndrome, spinal stenosis, neurogenic claudication, lumbar radiculopathy, patients with primary complaints of leg pain with numbness and or weakness, patients with a primary pain compliant that is vascular in origin, clinical evidence of progressive neurologic pathology, mechanical instability or other spinal pathology that requires surgical intervention, spine or visceral pain secondary to neoplasm, visceral pain in the upper abdomen rather than the pelvis, current diagnosis of fibromyalgia participants with significant cognitive impairment, participants with a condition currently requiring or likely to require use of diathermy or MRI or history of any other condition that in the opinion of the investigator could put the participant at risk or interfere with study results interpretation. (screening patient). 14. Participants involved in ongoing litigation and or injury claims or workers compensation claims. 15. Participation in a current clinical trial or within the preceding 30 days

Inclusion Criteria

Exclusion Criteria

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Female, aged 22-70
4. Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient)
5. Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations)
6. No changes to current regimen of medications for their pelvic pain for \> 4 weeks prior to screening
7. For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation
8. Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)

1. History of any active pelvic cancer
2. Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints
3. Concurrent pain management strategies within the past 3 months that may interfere or mask study intervention (e.g. pelvic floor physical therapy, shockwave therapy, trigger point injections, bladder instillations)
4. Any psychiatric or personality disorder at the discretion of the study physician. This does not include depression or generalized anxiety disorders that are stable.
5. Current symptomatic urinary tract infection (UTI) or more than 6 UTIs in past year
6. Severe or uncontrolled diabetes (A1C \> 7, documented in the last 3 months) or diabetes with peripheral nerve involvement
7. Interstitial cystitis diagnosis with Hunner's lesions as this is a severe inflammatory bladder condition that can only be treated with eradication of the lesions or a cystectomy. SNM would be be expected to help for IC with Hunner's lesions
8. Previously implanted with a sacral neuromodulation device or participated in a sacral neuromodulation trial
9. Subject with documented history of allergy to titanium, zirconia, polyurethane, epoxy, or silicone
10. Implantation of spinal cord stimulator and/or drug delivery pumps, whether turned on or off
11. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception
12. Current treatment for active malignancy (skin cancers excluded)
13. Patients with spinal pathology that could confound study results. This may include participants with cauda equina syndrome, spinal stenosis, neurogenic claudication, lumbar radiculopathy, patients with primary complaints of leg pain with numbness and or weakness, patients with a primary pain compliant that is vascular in origin, clinical evidence of progressive neurologic pathology, mechanical instability or other spinal pathology that requires surgical intervention, spine or visceral pain secondary to neoplasm, visceral pain in the upper abdomen rather than the pelvis, current diagnosis of fibromyalgia participants with significant cognitive impairment, participants with a condition currently requiring or likely to require use of diathermy or MRI or history of any other condition that in the opinion of the investigator could put the participant at risk or interfere with study results interpretation. (screening patient).
14. Participants involved in ongoing litigation and or injury claims or workers compensation claims.
15. Participation in a current clinical trial or within the preceding 30 days

Contacts and Locations

Study Contact

Angela Waldvogel, BSN

CONTACT

248-551-2572

Angela.Waldvogel@corewellhealth.org

Jennifer Giordano, BSN

CONTACT

248-551-3517

jennifer.giordano@corewellhealth.org

Principal Investigator

Kenneth Peters, MD

PRINCIPAL_INVESTIGATOR

Corewell Health William Beaumont University Hospital

Study Locations (Sites)

Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073

United States

Collaborators and Investigators

Sponsor: William Beaumont Hospitals

Kenneth Peters, MD, PRINCIPAL_INVESTIGATOR, Corewell Health William Beaumont University Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06

Study Completion Date2028-06

Study Record Updates

Study Start Date2025-06

Study Completion Date2028-06

Terms related to this study

Keywords Provided by Researchers

Women

Additional Relevant MeSH Terms

Chronic Pelvic Pain Syndrome